DE60228817D1 - THIENO(3,2-d)PYRIMIDINE UND FURANO(3,2-d)PYRIMIDINE UND DEREN VERWENDUNG ALS ANTAGONISTEN AN PURINERGEN REZEPTOREN - Google Patents

THIENO(3,2-d)PYRIMIDINE UND FURANO(3,2-d)PYRIMIDINE UND DEREN VERWENDUNG ALS ANTAGONISTEN AN PURINERGEN REZEPTOREN

Info

Publication number
DE60228817D1
DE60228817D1 DE60228817T DE60228817T DE60228817D1 DE 60228817 D1 DE60228817 D1 DE 60228817D1 DE 60228817 T DE60228817 T DE 60228817T DE 60228817 T DE60228817 T DE 60228817T DE 60228817 D1 DE60228817 D1 DE 60228817D1
Authority
DE
Germany
Prior art keywords
sub
conr
alkyl
aryl
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60228817T
Other languages
English (en)
Inventor
Roger John Gillespie
Joanne Lerpiniere
Claire Elizabeth Dawson
Suneel Gaur
Robert Mark Pratt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis Research Ltd
Original Assignee
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Research Ltd filed Critical Vernalis Research Ltd
Application granted granted Critical
Publication of DE60228817D1 publication Critical patent/DE60228817D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60228817T 2001-01-10 2002-01-10 THIENO(3,2-d)PYRIMIDINE UND FURANO(3,2-d)PYRIMIDINE UND DEREN VERWENDUNG ALS ANTAGONISTEN AN PURINERGEN REZEPTOREN Expired - Lifetime DE60228817D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0100620.4A GB0100620D0 (en) 2001-01-10 2001-01-10 Chemical cokpounds V
PCT/GB2002/000084 WO2002055524A1 (en) 2001-01-10 2002-01-10 THIENO(3,2-d)PYRIMIDINES AND FURANO(3,2-d)PYRIMIDINES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
DE60228817D1 true DE60228817D1 (de) 2008-10-23

Family

ID=9906567

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60228817T Expired - Lifetime DE60228817D1 (de) 2001-01-10 2002-01-10 THIENO(3,2-d)PYRIMIDINE UND FURANO(3,2-d)PYRIMIDINE UND DEREN VERWENDUNG ALS ANTAGONISTEN AN PURINERGEN REZEPTOREN

Country Status (8)

Country Link
US (2) US7384949B2 (de)
EP (1) EP1349861B1 (de)
JP (1) JP4390454B2 (de)
AT (1) ATE407935T1 (de)
CA (1) CA2434005A1 (de)
DE (1) DE60228817D1 (de)
GB (1) GB0100620D0 (de)
WO (1) WO2002055524A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003207734C1 (en) 2002-01-28 2009-10-08 Kyowa Kirin Co., Ltd. Methods of treating patients suffering from movement disorders
WO2003070241A1 (en) 2002-02-15 2003-08-28 Rigel Pharmaceuticals, Inc. Inhibitors of tubulin polymerization
JP2004137270A (ja) * 2002-09-26 2004-05-13 Nippon Nohyaku Co Ltd 新規除草剤、その使用方法、新規置換チエノピリミジン誘導体及びその中間体並びにそれらの製造方法
US8133870B2 (en) 2004-10-29 2012-03-13 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
JPWO2006137350A1 (ja) * 2005-06-22 2009-01-15 キッセイ薬品工業株式会社 新規なフロピリジン誘導体、それを含有する医薬組成物およびそれらの用途
ES2273599B1 (es) * 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US20070208040A1 (en) * 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
WO2010010908A1 (ja) * 2008-07-23 2010-01-28 協和発酵キリン株式会社 片頭痛治療剤
US20100093763A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093702A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
CA2813437A1 (en) 2010-10-08 2012-04-12 Abbvie Inc. Furo[3,2-d]pyrimidine compounds
CN104981247A (zh) 2012-09-06 2015-10-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
US9745320B2 (en) * 2013-01-18 2017-08-29 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2018237084A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC COMPOUNDS INTERACTING WITH RAS SUPERFAMIL FOR USE IN THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES AND FIBROTIC DISEASES
EP3675856A4 (de) 2017-08-31 2021-04-14 Corvus Pharmaceuticals, Inc. Verbindungen und verfahren zur modulation des adenosin-a2b-rezeptors und des adenosin-a2a-rezeptors
WO2022129376A1 (en) * 2020-12-18 2022-06-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) 6-6 or 5-6 fused bicyclic compounds comprising a pyri(mi)dine ring useful in the|treatment of infectious diseases
AU2022252182A1 (en) * 2021-03-29 2023-09-28 Gilead Sciences, Inc. Khk inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0436284A (ja) 1990-05-29 1992-02-06 Sumitomo Chem Co Ltd ジフェニルフロピリミジン誘導体、その製造法およびそれを有効成分とする除草剤
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
US6197788B1 (en) * 1997-11-26 2001-03-06 Vernalis Research Limited (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
WO1999035147A1 (fr) 1998-01-05 1999-07-15 Eisai Co., Ltd. Derives de purine et antagonistes du recepteur a2 d'adenosine utiles comme moyens de prevention/traitement du diabete
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
GB9819382D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9819384D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
US6841549B1 (en) 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
AU780527B2 (en) * 2000-02-25 2005-03-24 F. Hoffmann-La Roche Ag Adenosine receptor modulators

Also Published As

Publication number Publication date
ATE407935T1 (de) 2008-09-15
EP1349861B1 (de) 2008-09-10
US7384949B2 (en) 2008-06-10
JP4390454B2 (ja) 2009-12-24
CA2434005A1 (en) 2002-07-18
EP1349861A1 (de) 2003-10-08
WO2002055524A1 (en) 2002-07-18
GB0100620D0 (en) 2001-02-21
US20040097524A1 (en) 2004-05-20
US20080153820A1 (en) 2008-06-26
JP2004524293A (ja) 2004-08-12

Similar Documents

Publication Publication Date Title
DE60228817D1 (de) THIENO(3,2-d)PYRIMIDINE UND FURANO(3,2-d)PYRIMIDINE UND DEREN VERWENDUNG ALS ANTAGONISTEN AN PURINERGEN REZEPTOREN
IL156779A0 (en) Purine derivatives as purinergic receptor antagonists
ATE424207T1 (de) Triazoloä4,5-düpyrimidinderivate und ihre verwendung als antagonisten purinerger rezeptoren
ATE405270T1 (de) Pyrrolo 2,3-d pyrimidine und deren verwendung als purinreceptor antagonisten
ATE307132T1 (de) Purin derivate als a2b adenosin rezeptor antagonisten
HK1068334A1 (en) Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
MXPA05010621A (es) Pirimidinonas sustituidas.
EP2258372B8 (de) A2A Antagonisten zur Behandlung von motorischen Störungen
GEP20084357B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
DK1107973T3 (da) Hidtil ukendte thieno(2,3-D)pyrimidindioner, fremgangsmåde til deres fremstilling og anvendelse deraf i terapi
WO2004094431A3 (en) 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
WO2003068776A1 (fr) Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine
CA2375671A1 (en) 4-phenyl-pyrimidine derivatives
WO2003020723A1 (fr) Derive de [1,2,4]triazolo[1,5-a]pyrimidine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition